| Matthew M Grabowski, | |
|
9500 Euclid Ave, Na21, Cleveland, OH 44195-0001 | |
| (412) 418-9659 | |
| Not Available |
| Full Name | Matthew M Grabowski |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 10 Years |
| Location | 9500 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891132437 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 57.024438 (Ohio) | Secondary |
| 207T00000X | Neurological Surgery | 35.134479 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
Culminating a nearly 10 year effort, researchers have determined the atomic resolution structure of a key molecule that translates signals from a cell's local environment into a language that the cell can understand and use.
A public inquiry into conditions and care at Stafford hospital in Stafford, England heard that the hospital was violating basic human rights of the patients. The counsel for Cure the NHS, a campaign group set up by relatives of some of the people who died at the hospital after receiving inadequate treatment established the fact that the standard of care constituted inhuman and degrading treatment at the facility.
Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
The March/April issue of USAID's "FrontLines" focuses on access to safe water and neglected tropical diseases.
› Verified 9 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Culminating a nearly 10 year effort, researchers have determined the atomic resolution structure of a key molecule that translates signals from a cell's local environment into a language that the cell can understand and use.
A public inquiry into conditions and care at Stafford hospital in Stafford, England heard that the hospital was violating basic human rights of the patients. The counsel for Cure the NHS, a campaign group set up by relatives of some of the people who died at the hospital after receiving inadequate treatment established the fact that the standard of care constituted inhuman and degrading treatment at the facility.
Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
The March/April issue of USAID's "FrontLines" focuses on access to safe water and neglected tropical diseases.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew M Grabowski, 9500 Euclid Ave # Ca-51, Cleveland, OH 44195-0001 Ph: (216) 444-2200 | Matthew M Grabowski, 9500 Euclid Ave, Na21, Cleveland, OH 44195-0001 Ph: (412) 418-9659 |
News Archive
Culminating a nearly 10 year effort, researchers have determined the atomic resolution structure of a key molecule that translates signals from a cell's local environment into a language that the cell can understand and use.
A public inquiry into conditions and care at Stafford hospital in Stafford, England heard that the hospital was violating basic human rights of the patients. The counsel for Cure the NHS, a campaign group set up by relatives of some of the people who died at the hospital after receiving inadequate treatment established the fact that the standard of care constituted inhuman and degrading treatment at the facility.
Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.
Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.
The March/April issue of USAID's "FrontLines" focuses on access to safe water and neglected tropical diseases.
› Verified 9 days ago
Jonathan J Rasouli, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: Cleveland Clinic 9500 Euclid Ave S-40, Cleveland, OH 44195 Phone: 216-444-9580 | |
Eric Herring, Neurological Surgery Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-3472 | |
Prakash Kotagal, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 | |
Dr. Gene Henry Barnett, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 216-444-5381 | |
Dr. Sara Alsulaimani, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave # Na-23, Cleveland, OH 44195 Phone: 440-226-1283 | |
Alan R Cohen, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-3004 Fax: 440-449-1555 | |
Dr. Seth Alan Hoffer, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave., Dept Of Neurosurgery, Univ Hospitals Of Cleveland, Cleveland, OH 44106 Phone: 216-844-3004 Fax: 216-844-3014 |